{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 30,
  "pageCount": 51,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a mechanism of action diagram illustrating 'Therapy Enhanced Synthetic Lethality'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/30",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.15,
        "x": 0.82,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Therapy Enhanced Synthetic Lethality: Targeted therapy kills low copy number cells, driving population toward ecDNA-reliant high copy number cells; ecDTx kills ecDNA-reliant high copy number cells; Together, all oncogene amplified cells are killed",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40510e39-121a-4ae0-943f-3f05964fed54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.15,
        "x": 0.42,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Oncogene copy number",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6468438c-f6a1-4a08-a19a-57712c0422ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Tumor volume over time in FGFR2amp gastric cancer CDX",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05e8ee5a-533d-460a-8779-4a1a9835235d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Therapy Enhanced Synthetic Lethality mechanism",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba981c37-f90a-4e93-875a-7b8b51fe1319",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.12,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "FGFR2 inhibition with infigratinib resulted in minimal, transient anti-tumor activity, consistent with clinical experience. When combined with BBI-355, extended synergistic tumor regression observed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0524b7f5-7590-4864-a48e-f06ccd557082",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Significance by unpaired t-test; p = 0.0156. Significance by ordinary one-way ANOVA with Tukey's multiple comparisons; p<0.0001",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e88dc62-250a-4dca-b009-83e3e540d92e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BBI-355 demonstrated synergistic combination activity in preclinical models of cancer indications in which single agent targeted therapies have not proven effective in the clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bcd3d66-1cae-4963-8725-e88693c3c3cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "efee0ddb-ce0a-434a-814c-2abb440316d7",
      "evidence": "diagram/process: Therapy Enhanced Synthetic Lethality mechanism",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "synthetic-lethality",
      "slug": null,
      "matchId": "2aaf799b-1eb5-4ef9-896a-c48d0bb0d067",
      "evidence": "Therapy Enhanced Synthetic Lethality mechanism diagram",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}